Since the late 1990s, Biovest's primary focus has been the commercialization of personalized immunotherapies. That work will continue under the Biovest name. "The spin-off of Cell Culture Company will ensure that our instrument and CMO customers will be better served through increased focus and investment," said Christiaan Engstrom, president, Cell Culture Company President.